Index

Tables, figures, and case studies are indicated by appending “t”, “f”, or “c” to the page number. Contents of tables are not indexed separately.

A
accelerated assessment mechanisms, 3–4
Active Implantable Medical Device Directive (AIMDD)  
repeal of, 98–99  
transition from, 92
active implantable/active medical devices  
classification change for, 60  
classification rules for, 105t  
legal framework for, 79–84  
MDR classification rules for, 105t
Active Substance Master File (ASMF): combination products, 198
Advanced Therapy Medicinal Products (ATMPs), 21–22
advertising and promotion, 31–42  
abbreviated ads as reminders, 34  
comparative advertisements, 38  
content for general public, 35–36  
contents for HCPs, 33–34  
EFPIA goals and code, 32–33  
endorsements by HCPs, 33  
enforcement by competent authorities, 48  
gifts/donations/hospitality to HCPs, 34–35  
HCPs, 33–34  
internet, 37  
jurisdictions for, 39–40  
by MAH, 33, 36  
market surveillance, 38–39  
medical devices, 40  
nonauthorised products, 37–38  
off-label information, 37–38  
OTCs, 36  
preapproval of material, 39–40  
press releases, 36–37  
regulatory framework, 31–32  
regulatory strategy for, 52  
sales representatives/sample distribution, 33–34  
scientific service by MAA, 39  
self-regulation, 32–33  
transfers of value disclosures for HCPs, 35  
affiliated countries and competent authorities, 75–77t
animal models  
nonclinical testing, 149c  
preclinical device testing, 149c
authorised representatives: conformity assessment, 130, 169t
B
Belgium: advertising preapproval, 39  
bench testing for devices, 148–149c
biocompatibility testing  
nonclinical studies, 148c, 149c  
preclinical test plan, 143  
requirements from standards and risk management, 144–145
biological medicinal products: human/veterinary variations, 21
Biologics Working Party (BWP), 21
biosimilar medicinal products  
pharmaceutical regulation evolution, 22  
therapeutic interchangeability, 22
borderline product classification, 114–115
C
CE Mark  
compliance confirmation with, 69
countries requiring, 186
for IVDs, 127–128
Centralised Procedure
authorisation system, 20
Brexit effects for UK, 10
combination products, 192
EMA committee evaluation of products, 7, 14
evaluation of products, 14
MAA evaluation by EMA, 2
pan-European registration system, 19
product criteria for use, 19
clinical evaluation and clinical investigations
bench testing, 73, 148c, 149c
CE Mark requirements, 152
Clinical Evaluation Report (CER), 152
c clinical pathway review, 155
c clinical strategy plan, 154
c clinical trial essentials, 155
c common mistakes in, 155–156
elements of device evaluation, 152–153
equivalence to existing device, 153
GCP and quality in, 155
MDD, EU MDR definitions of, 44
objectives of clinical investigation, 153
performing clinical investigation, 154–155
planning the evaluation, 153–154
report required, 152
Clinical Evaluation Report (CER), 152–154
Clinical Investigation Protocol (CIP), 85, 155
combination products, 191–200
boundary products, 193
conformity assessment requirements, 197
determination of registration pathway, 192
directives and guidance documents, 195–196
heparin and AIMD, 199c
IVDs and CDx, 198
labelling requirements, 199
medicinal product/device delineation, 191–192
pharmaceutical consultation procedure, 197–198
postmarket surveillance requirements, 199
product classification by PMOA, 192–195
quality system requirements, 198–199
regulatory classification determination, 196
set for local anaesthesia with lidocaine, 199–200c
sunblock cream/embedded barrier for vitiligo, 200c
in vitro fertilisation/transplant organs or tissue, 199c
Committee for Advanced Therapies (CAT)
combination products, 198
EMA responsibility for, 78
responsibilities of, 4, 8
Committee for Medicinal Products for Human Use (CHMP)
PRAC recommendation endorsements, 47
responsibilities of, 7
Committee for Medicinal Products for Veterinary Use (CVMP), 8
Committee for Orphan Medicinal Products (COMP), 8
Common Specification (CS): GSPRs conformity verifications, 139
Common Technical Specifications (CTS): for IVDs, 128
comparative matrix of legislation, 201–248
Competent Authorities for Medical Devices (CAMD), 44, 78
conformity and postmarket surveillance (devices)
clinical followup for AIMDs and MDs, 174–175
Eudamed, 180–181
feedback mechanisms for, 171–172
Field Safety Corrective Action (FSCA), 172
follow-up investigation, 178–179
FSCAs and FSNs, 179
GPSD, MDD, and EU MDR relationship, 172–173
incidents and criteria for reporting, 176–178
medical device global vigilance, 180
PMS vs vigilance, 180–181
postmarket surveillance procedures, 173
risk management in device industry, 174
surveillance and control provisions, 181–182
trend reporting, 179
Concerned Member States (CMS): RMS evaluation for MA, 19
conformity assessment
AIMDD documentation, 160
AIMDD procedure, 164f
authorised representatives, 169–170, 169t
CE marking process, 158–159
Class I device, self-declaration/self-certification, 164f
Class IIa procedure, 163f
Class III device options, 162f
Class IIIb procedures, 163f
conformity assessment in, 50
documentation for, 161
EC type-examination, 168t
EC-type examination, 166
full quality assurance system, 167, 168t
high-risk IVD procedure, 167f
internal production control, 166, 168t
IVD procedure, 165f
IVDD Annex II list b procedure, 166f
IVDD documentation, 161t
for IVDs, 130
MDD conformity assessment documentation, 161t
Notified Bodies in, 169
procedures for, 160t
product quality assurance, 167, 168t
product risk class and, 159, 162, 165–166
product verification, 167, 168t
production quality assurance, 166–167, 168t
quality system requirements, 167, 169
self-testing IVD procedure, 165f
custom-made devices: Essential Requirements for, 85

D
Danish Promotion Code, 34
Decentralised Procedure (DCP)
CMDh, 8, 10
market access mechanism, 19
Declaration of Conformity (DoC)
compliance demonstration and, 69
under EU IVDR, 130
intended use of device and, 81
for IVDs, 117, 127–128
legal manufacturer and, 94
management of, 59
manufacturer/authorised representative and, 101
for placing on the market, 84
Design Traceability Matrix, 145
Directive, in legal framework, 98
drug-device combination products (DDCs) classification, 107–108
Drug-Eluting Stent (DES) and medicinal substance, 148–149c

E
electrical magnetic disturbance testing, 147
electrical safety, 147
Electrotechnical Commission (CENELEC) standards, 139
enforcement
medical devices
CE marking errors, 45
Eudamed communications, 46
notified bodies, 46
Safeguard Clause, 45
medicinal product pharmacovigilance, 47
medicinal products
advertising and promotion, 47–48
GMP compliance, 47
recalls, 47
Essential Principles concept, 136–138
Essential Requirements (ER)
clinical investigation vs clinical evaluation, 152–153
compared to GSPRs, 144
conformity assessment for, 101
consensus standards definition by, 139
custom-made devices, 85
harmonised technical standards for, 91
intended purpose and, 81
for IVD manufacturer processes, 125
legal documents, 18
legislative harmonisation and compliance, 69, 127–128
manufacturer GSPR demonstration, 152
safety and performance vs technical documentation, 23–24
EU laws and regulations
basic legislation for, 14
codification/clarification of pharmaceutical directives, 19
current regulation evolution, 17–19
economic issues, 16–17
EU In Vitro Diagnostics Regulation (EU IVDR), 52
falsification and counterfeiting, 17
General Data Protection Regulation (GDPR), 52
information availability and transparency, 16
IVDD, 26
medical device regulation evolution, 23–24
medical product regulation development, 14–15
patient advocacy and involvement, 16
pharmaceuticals regulation, 20
product innovation, 15–16
Regulation (EC) No 726/2004, 52
Regulations (EC) 141/2000 and 847/2000, 36
traditional herbal medicinal products, 23
unsafe product consequences, 15

EU MDR and EU IVDR
authorised representative agreement contract forms, 93
classification and conformity assessment, 60
clinical evidence, trials, and regulatory compliance, 58–59
Commission recommendation, 88, 88t
delegated and implementing acts, 62
EC working groups, 79, 80–81t
economic operators
importers and distributors, 78
manufacturers and authorised representatives, 78
Essential Requirements vs GSPRs, 152
governance, 61–62
governance structure, 61f, 90f
healthcare establishments, 78
implementation of MAID goods package, 56–57
implications of, 62–63
improved elements, 87–88
industry representation/trade associations, 79, 81t
institutional cooperation and consensus building, 78–79
interpretation of medical device law
Commission as an arbitrator, 91
Commission guidance, 89–90
courts, 88
guidance from Member States, 91
guidance from other sources, 91
ISO 13485 in transition to, 169
legal system evolution, 92
market access mechanism, 58
MDD and EU MDR device definitions, 82t
MEDDEV guidance documents, 86–87t
medical device laws
  key directives, 79
  scope of device directives, 79
national enforcement, 91–92
NBOG Best Practice Guide, 89t
notified bodies changes with, 58
overview, 94
own-brand labelling and reprocessing, 60–61
postmarket surveillance and vigilance, 59–60
product liability, 92–93
proposed IVDR classification rules, 59f
QMS requirements and ISO 13485, 166–167
scope of
  authorised representative, 87
  clinical investigation devices, 85
  custom-made devices, 84–85
  manufacturer, 85–87
  medical devices and active implantable medical devices, 56, 79–84
significance of technical standards, 91
stakeholders
  MDCG, 73
  Member States, relevant countries, 73
supply chain controls, 56f
supply chain vigilance obligations, 93–94
timeline for adopting/transitional regime, 62
traceability, 57–58
EU regulatory affairs
advertising and promotion, 31–42
clinical evaluation and clinical investigations, 151–156
combination products, 191–200
comparative matrix of legislation, 201–248
EMA and other regulatory bodies, 1–12
enforcement and competent authorities, 43–48
history of regulations, 13–30
medical device compliance/postmarket requirements, 171–183
medical device conformity assessment procedure, 157–170
medical device legislation and classification, 97–120
medical device national particularities, 185–190
medical device preclinical testing, 143–150
medical devices legal system, 65–96
new MDR and IVDD regulation, 55–64
regulatory strategy, 49–54
safety and performance requirements/technical documentation, 135–142
in vitro diagnostic devices (IVDDs), 121–134
EU Treaty, 14
Eudamed
  competent authority communications, 46
  market surveillance and vigilance, 181–182
European Commission (EC) GSPR requirements, 139
European Economic Area (EEA): CE marking for, 186
European Federation of Pharmaceutical Industries and Associations (EFPIA)
  CE marking requirements, 186
  codes of conduct, 32–33
  product distribution, 34–35, 39
European Standardization Committee (CEN) safety standards, 139
F
falsification and counterfeiting laws and regulations, 17
Field Safety Corrective Action (FSCA), 172
Field Safety Notices (FSNs), 179
France: advertising preapproval, 39
G
General Electrical Safety Standard, 147
General Product Safety Directive (GPiSD), 173
general safety and performance requirements (GSPRs)
  applicable standards identification, 140
  checklist for, 137–138t
  device registration requirements, 130
  historical foundations for, 135–136
  IVDD revision by EU IVDR, 130–131
  manufacturer GSPR demonstration, 101, 152
  predicate device requirement, 141
  referencing applicable standards, 141
  regulatory status of European standards, 139
  requirements for, 136, 137
  standards and common specifications use for, 139
  technical documentation, 140–141
terminology change, 152
Germany: Safeguard Clause action (catgut), 181
Global Harmonization Task Force (GHTF)
  Essential Principles concept, 136
  guidance document from, 154
  IMDRF succession to, 180
  IVD risk classification of IVDs, 126–127
  risk-based device classification, 120
  STED developed by, 140
glossary, 249–267
GMP compliance/certificate
  Marketing Authorisation Holder (MAH), 47
Good Clinical Practice (GCP)
clinical investigation of devices, 154–155

Guidance documents
European Commission Consensus Statements, 88t
European Commission documents, 88t, 89–90
MDCG, 99
MEDDEV Commission guidance, 86–87t
NBOG Best Practice Guide, 89t
TEAM-NB, 91

H
harmonised standards
GSFP compliance demonstration and, 139–140
for IVDs, 127–130
medical device regulation, 24–25

health monitoring measures
actions against general threats to public health, 45
comparison with Safeguard Clause, 181–182, 181t

healthcare professionals (HCPs): advertising and promotion to, 33–34

heated sleep apnea device, 148c

human/veterinary product variations, 21

I
In Vitro Diagnostic Devices Regulation (EU IVDR), 55–63, 103–114
in vitro diagnostic (IVD) medical device, 121–134
classification disputes, 117
classification process, 115–117
essential requirements for, 127
EU laws and regulations, 26
IVDD and IVDR classification rules, 118–119
IVDD and IVDR scope, 122–123
accessories, 124
companion diagnostic (CoDx), 125–126
device performance testing, 124
in-house developed, 125
IVD use, 123
laboratory use products and IVD devices, 124t
medical device legislation and classification, 122–123
research-only, 124–125
specimen receptacles, 123–124
specimens examined, 123
IVDD revision, 130–131
manufacturer process, 125
pan-European requirements, 121
regulations for safety, 131
risk-based classification lists for, 126–127

In Vitro Diagnostic Medical Devices Directive (IVDD), 98–99

In Vitro Diagnostic Regulation (EU IVDR), 103, 192
in-house produced devices, 61

Instructions for Use (IFU)
contents for IVDs, 129
device evaluation and, 152

International Council on Harmonisation (ICH), 45

International Electrotechnical Commission (IEC)
medical device standards, 144–145, 147–148
standard use in EU, 78, 91

International Federation of Pharmaceutical Manufacturers Association (IFPMA)
code of ethics, 31, 33, 35
promotional material approval, 39

International Medical Device Regulators Forum (IMDRF)
consensus standards, 139–140
coordination and cooperation enhancement, 45
GHTF basis for, 180
medical device global vigilance, 180

International Organization for Standardization (ISO)
consensus standards definition by, 139
standard harmonisation, 78
use in preclinical testing, 144

invasive devices: classification rules for (MDR), 104t
ISO 13485
gap assessment for EU MDR and EU IVDR transition, 169, 172
harmonised quality system model, 128–129, 140
production quality assurance model, 166–167
QMS requirements, 129
review of feedback, 173, 180, 182

ISO 14971
FSCA warning methods, 179
harmonised standards for risk management, 128
postmarket surveillance and vigilance, 172
risk management requirements, 140, 180, 182

Italian Farmaindustria Code, 34

Italy: advertising preapproval, 39

J
Joint Action on Market Surveillance (JAMS), 3, 44
Joint Immediate Action Plan, 46

L
labelling requirements
combination products, 199
for IVDs, 129–130
language requirements for IVDs, 129–130
legal framework/legislation
active implantable/active medical devices, 79–84
advertising and promotion, 31–32
comparative matrix of legislation, 201–248
Directive defined, 98
mechanism for medicinal products for human use, 18–19
medical devices, 55–63, 64–96, 97–120
medical product, 18
Opinion, 98
product legislation, 17–18
Recommendation, 98
Regulation, 98
Regulation defined, 98
See also medical device legal system; medical device legislation and classification

lifecycle of drugs, 22–23

M
Market Surveillance Operations Group (MSOG), 181
Marketing Authorisation Application (MAA)
  human-veterinary variations, 20–21
  regulatory strategy for, 52
Marketing Authorisation Holder (MAH)
  advertising to general public, 36
  advertising to healthcare professionals, 33
  EMVO, 47
  GMP compliance, 47
  scientific service implementation, 39
Medical Device Coordination Group (MDCG)
  borderline combination products, 193
  centralised governance, 73, 79
  classification disputes, 117–119
  CTS adoption by implementing act, 128
  decisions on product qualification, 56
  device classification determination, 56
  enforcement and surveillance, 60–62, 73, 92
  regulatory classification determination, 193, 196–197, 199
  regulatory strategy development, 52
  regulatory strategy information, 52
  responsibilities of, 90–91
  revised guidance from, 144
Medical Device Directive
  repeal of, 98–99
  transition from, 92
medical device legal system
  clinical evaluation cycles, 73f
  Commission as an arbitrator, 91
  conformity assessment for AIMDs, 71f
  conformity assessment for IVD, 72f
  conformity assessment procedures, 70f
  custom-made devices, 79–85
  development, 25–26
  EC working groups and activities, 80–81t
  EMA in, 78
  enforcement, 45
    market surveillance, 45–46
  enforcement and competent authorities, 45–46
  Essential Requirements and technical standards, 91
  industrial trade associations, 81t
  key principles
    compliance verification, 69
    essential requirements compliance, 69–73
    legislative process, 64 –66, 67f
    manufacturer role in, 85
  MDD and EU MDR device definitions, 82t
  MEDDEV guidance documents, 85–86t
  medical device laws, 79–84
  national enforcement, 91–92
  new approach regulatory philosophy, 67–68, 68t
  new legislative framework (NLF), 71
  regulation evolution and harmonisation, 23–25
medical device legislation and classification, 97–120
  classification disputes, 117
  classification matrix, 102t
  classification principles
    basic principles of application, 103–104
    rule-based approach for, 101–103
    in vitro diagnostic regulation, 103
  EU MDR and MDD rules
    active devices, 114
    borderline products, 114–115
    comparison, 109–114t
    invasive devices, 114
    non-invasive devices, 114
    software, 114–115
    special rules, 114
    without intended medical use, 115
  IVD classification process, 115–117, 116t
  IVDD and IVDR rule comparison, 118–119t
  key concepts for classification
    biological effect, 107
    energy use, 107
    invasiveness, 107
    time period, 105
  legislation and regulatory framework
    definitions, 98
MDR rules
  for invasive devices, 104t
  special, 106t
  medical device directives, 98–99
  medical devices definition and expansion of, 99–100
  accessories, 100
  custom-made devices, 100
  intended purpose, 100
  specimen receptacles, 100
  in vitro diagnostic medical device, 100
  non-invasive devices rules, 103t
  requirements, 100–101
  transition to EU MDR and EU IVDR, 99
  unclassified devices, 102
medical device national particularities
  CE marking for, 185
directives and regulations for, 186t
EU outermost regions, 186t
language and labelling, 186–188
national languages, 188t
notification requirements, 188–189
translation requirements, 187t
Medical Device Vigilance System, 172, 175
Medical Devices Coordination Group (MDCG), 73
Medical Devices Regulation (EU MDR), history of, 55–63
Medicinal Product Directive (MPD) (Directive 2001/83/EC), 18
medicinal products enforcement and compliance
enforcement, 47–48
enforcement and competent authorities, 46–48
for human use, 18–19
Member States
competent authorities and affiliated countries, 75–77t
enforcement by competent authorities, 43–48
EU MDR and ER IVDR significance for, 73–78
interim device actions under Safeguard Clause, 181
Marketing Authorisation Application (MAA) in, 19
Mutual Recognition Procedure (MRP)
criteria for use of, 19
evaluation of products, 14
N
national competent authorities, 43–48
action on medical device safety, 45–46
cooperation and coordination for enforcement, 44–45
coordination and cooperation enhancement, 45
medical devices, 45
member states and affiliated countries, 75–77t
national regulatory bodies, 44
National Procedure: marketing authorisation for
medicinal products, 19
new legislative framework (NLF) for devices, 71
nonclinical pharmacodynamics, 149c
non-invasive device classification rules, 103t
Notified Bodies responsibilities, 46
Notified Body Operations Group (NBOG)
best practices guides, 89t
guidance document from, 89, 99–100
O
Opinion in legal framework, 98
Organisation for Economic Co-operation and Development (OECD)
EMA collaboration, 10
orphan medicinal products (OMPs)
orphan designation benefits and criteria, 8
over-the-counter (OTC) products
advertising to general public, 36
Own-Brand Labelling (OBL), 60–61
P
Periodic Safety Update Report (PSUR)
device technical documentation, 141
PMCF in, 175
for technical documentation, 141
periodic safety update reports (PSURs)
sharing through Eudamed, 46
pharmaceutical directives
ATMPs, 21–22
development of regulatory system, 20
human–veterinary MAA variations, 20
Pharmaceutical Inspection Convention (PIC)
coordination and cooperation enhancement, 45
pharmacokinetic (PK) testing with combination product, 149c
Pharmacovigilance Risk Assessment Committee (PRAC), 45
postmarket clinical follow-up (PMCF)
Class III and implantable devices, 152–153, 174–175
manufacturer’s obligations for, 71
use in clinical strategy, 154
postmarket surveillance (PMS), 174
combination product requirements, 199
device technical documentation, 141
manufacturer, 45–46
preclinical testing of devices
biocompatibility testing, 145, 148c, 149c
Design Traceability Matrix for, 145
electrical safety and magnetic disturbance testing, 147
nonclinical studies, 145, 149
packaging validation, 146
performance testing, 145
preclinical test plan
regulatory requirements, 144
standards requirements, 144
user requirements, 144
risk management requirements, 144
shelf life (aging) studies, 147
software verification and validation, 147
statistical methods, 148
sterilisation validation, 146–147
transport studies, 146
usability (human factors) studies, 147
predicate device: GSPRs requirements, 141
Prescription Medicines Code of Practice Authority (PMCPA), 39
primary mode of action (PMOA): combination prod-
ucts, 192–193

Q
Qualified Person (QP/QPPV)
in recall decisions, 47

Quality Management System (QMS)
for clinical evaluation procedures, 154
in clinical investigation and evaluations, 154
for combination products, 198–199
in conformity assessment, 162
conformity assessment in, 50
EU IVDR requirements, 129
PMS requirements, 46
postmarket surveillance in, 45–46, 173
regulatory strategy for, 52
technical documentation for, 140

quality systems and inspectorate process for IVDs,
128–129

R
Reference Member State (RMS): MAA evaluation, 19
Regulation, in legal framework, 98
regulatory authorities
EMA, 1–5, 7–10
European Medicines Regulatory Network, 5–7
regulatory strategy
confirming strategy, 52–53
developing and implementing, 50–52
documentation of, 52–53
information resources for development, 52
key questions during development, 51t
market considerations in, 49–50
review/update of; 53
reprocessing, 61
risk management plan (RMP)
biocompatibility testing, 144–145
in device industry, 174
preclinical device testing, 144

S
Safeguard Clause
action by Member States, 181
action on conforming devices, 45
comparison of health monitoring measures, 181–182,
181t
scientific service implementation by MAH, 39
software
EU MDR and EU IVDR reclassification of, 56, 60,
81
GSPRs requirements, 136, 145
with medical devices, 26, 100, 114–115, 122, 193
preclinical device testing, 147
verification and validation of, 147, 148c
vigilance for, 175
Summary of Product Characteristics (SmPC), 32–35,
37
Summary of Safety and Clinical Performance (SSCP),
152
Summary Technical Documentation (STED),
140–141
supply chain controls: new MDR and IVDD regulation,
56–57

t
technical documentation
of Essential Requirements compliance, 129
EU MDR and EU IVDR, 140–141
for IVDs, 129
therapeutic interchangeability: biosimilar medicinal
products, 22
toxicity studies: preclinical device testing, 149c	raceability regulations, 57–58
traditional herbal medicinal product regulation and
evaluation, 23
Transmissible Spongiform Encephalopathy (TSE),
15
trend reporting, 179

U
unique device identifiers (UDI), 52, 57, 129, 182
United Kingdom (UK)
advertising and promotion, 39–40
Brexit impact on medical devices, 186
usability testing, 148c

V
Vaccine Antigen Master File (VAMF)
EU regulations, 21
veterinary vaccines, 23
vaccines, 21
veterinary medicinal products
CMDv, 18
CVMP role in authorisation, 8
national competent authorities for, 6–7
pharmaceutical regulation evolution, 22–23
regulatory agencies for, 2–3, 4–5
regulatory principles, 22–23
variations to MAAs, 20–21
veterinary/human product variations, 21
vigilance procedures for IVDs, 128–129

W
wrongly affixed CE-marking, 45